Edoxaban Sandoz
Direct oral anticoagulant (DOAC) – Factor Xa inhibitor
Quick Facts About Edoxaban Sandoz
Key Takeaways
- Edoxaban Sandoz is a once-daily direct oral anticoagulant (DOAC) used to prevent stroke in atrial fibrillation and treat venous thromboembolism (DVT/PE).
- The 15 mg dose is a reduced-strength formulation for patients with low body weight (≤60 kg), moderate-to-severe renal impairment (CrCl 15–50 mL/min), or those taking certain P-glycoprotein inhibitors.
- Unlike warfarin, edoxaban does not require routine blood monitoring (INR checks) and has fewer food interactions, but bleeding risk must still be carefully managed.
- Edoxaban should not be used in patients with mechanical heart valves, moderate-to-severe mitral stenosis, or creatinine clearance above 95 mL/min (reduced efficacy observed in trials).
- A specific reversal agent (andexanet alfa) is available for emergency situations involving life-threatening or uncontrolled bleeding.
What Is Edoxaban Sandoz and What Is It Used For?
Quick Answer: Edoxaban Sandoz is a prescription anticoagulant (blood thinner) that works by selectively inhibiting Factor Xa, a key enzyme in the blood clotting cascade. It is used to prevent stroke in atrial fibrillation and to treat blood clots in the legs (DVT) and lungs (PE).
Edoxaban belongs to the class of medicines known as direct oral anticoagulants (DOACs), sometimes also referred to as novel oral anticoagulants (NOACs). Unlike traditional anticoagulants such as warfarin, which affect multiple steps in the coagulation cascade through vitamin K inhibition, edoxaban works by directly and selectively blocking Factor Xa. This factor plays a central role in converting prothrombin to thrombin, the enzyme that ultimately converts fibrinogen to fibrin, forming the structural basis of a blood clot.
By inhibiting Factor Xa, edoxaban reduces the body's ability to form blood clots. This mechanism makes it effective in preventing thromboembolic events — situations where blood clots form in the heart or blood vessels and travel to block circulation in critical organs such as the brain (causing stroke) or lungs (causing pulmonary embolism). The ENGAGE AF-TIMI 48 trial, a landmark randomised controlled trial involving over 21,000 patients, demonstrated that edoxaban was non-inferior to warfarin for stroke prevention in atrial fibrillation while causing significantly fewer major bleeding events.
Edoxaban Sandoz is a generic formulation manufactured by Sandoz, containing the same active substance (edoxaban tosilate monohydrate) as the originator product. Generic medicines must meet the same rigorous bioequivalence standards set by the European Medicines Agency (EMA) to ensure identical efficacy and safety profiles.
Approved Indications
Edoxaban Sandoz is licensed in the European Union and many other countries for two primary indications:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75, hypertension, diabetes mellitus, or symptomatic heart failure (NYHA class ≥II).
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Treatment with edoxaban for venous thromboembolism (VTE) is initiated after at least 5 days of initial parenteral anticoagulation therapy (e.g., low molecular weight heparin).
Mechanism of Action
Edoxaban is a highly selective, direct, and reversible inhibitor of Factor Xa. It inhibits both free Factor Xa and prothrombinase activity. Factor Xa is the convergence point of the intrinsic and extrinsic coagulation pathways, making it a strategic target for anticoagulation. By inhibiting Factor Xa, edoxaban decreases thrombin generation, prolongs clotting times, and reduces thrombus formation without directly affecting existing clots.
Following oral administration, edoxaban is rapidly absorbed with peak plasma concentrations reached within 1 to 2 hours. The oral bioavailability is approximately 62%. The drug has a half-life of 10 to 14 hours, supporting once-daily dosing. Approximately 50% of the absorbed dose is eliminated renally, with the remainder metabolised via hydrolysis, conjugation, and oxidation by CYP3A4 (a minor pathway). This dual elimination pathway means that renal impairment significantly affects drug exposure, necessitating dose reduction in patients with moderate-to-severe renal impairment.
Why the 15 mg Dose?
The standard dose of edoxaban for most indications is 60 mg once daily. However, the dose is reduced to 30 mg once daily in specific patient populations. The 15 mg tablet is primarily used in the context of further dose adjustments or specific clinical scenarios where the 30 mg dose requires halving, as well as during transition periods from or to other anticoagulants. Your doctor will determine the appropriate dose based on your individual clinical profile, including renal function, body weight, and concomitant medications.
Edoxaban should not be used in patients with creatinine clearance (CrCl) above 95 mL/min for stroke prevention in atrial fibrillation. The ENGAGE AF-TIMI 48 trial showed a trend towards reduced efficacy in this subgroup compared to warfarin. This is a unique consideration among DOACs and is reflected in the product labelling by both the EMA and FDA.
What Should You Know Before Taking Edoxaban Sandoz?
Quick Answer: Before starting edoxaban, your doctor must assess your kidney function, bleeding risk, and current medications. Edoxaban is contraindicated in active bleeding, severe liver disease, and patients with mechanical heart valves. Special caution is needed during pregnancy and breastfeeding.
Contraindications
Edoxaban Sandoz must not be used in the following situations:
- Active clinically significant bleeding: This includes gastrointestinal bleeding, intracranial haemorrhage, or any other active pathological bleeding at the time of treatment initiation.
- Severe hepatic impairment: Patients with liver disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients classified as Child-Pugh B or C, should not receive edoxaban.
- Hypersensitivity: Known allergy to edoxaban or any of the excipients listed in the product formulation.
- Lesions or conditions at significant risk of major bleeding: This includes current or recent gastrointestinal ulceration, malignant neoplasms at high bleeding risk, recent brain or spinal injury, recent brain, spinal, or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.
- Uncontrolled severe hypertension.
- Concomitant treatment with any other anticoagulant agent (e.g., unfractionated heparin, low molecular weight heparins, warfarin, dabigatran, rivaroxaban, apixaban), except under specific circumstances of switching anticoagulant therapy or when unfractionated heparin is given at doses necessary to maintain a patent central venous or arterial catheter.
Warnings and Precautions
Several important warnings apply to the use of edoxaban. Your prescribing physician should evaluate these carefully before and during treatment:
Bleeding risk: As with all anticoagulants, edoxaban increases the risk of bleeding. Patients should be closely monitored for signs and symptoms of bleeding, particularly during the first year of treatment. Any unexplained fall in haemoglobin or blood pressure should prompt a search for a bleeding source. Factors that increase bleeding risk include concurrent use of other drugs affecting haemostasis (aspirin, NSAIDs, antiplatelet agents), advanced age, low body weight, renal impairment, and thrombocytopenia.
Renal function monitoring: Since approximately half of the absorbed edoxaban dose is eliminated through the kidneys, renal function (creatinine clearance) must be assessed before starting treatment and should be re-evaluated periodically during therapy, particularly in situations where renal function may decline (e.g., hypovolaemia, dehydration, concurrent use of nephrotoxic medications). The dose of edoxaban must be adjusted based on renal function.
Mechanical heart valves: Edoxaban has not been studied in patients with mechanical heart valves. Its use is not recommended in this population due to the lack of safety and efficacy data. Warfarin remains the anticoagulant of choice for patients with mechanical prosthetic valves.
Haemodynamically unstable PE: Edoxaban should not be used as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or who may receive thrombolysis or pulmonary embolectomy.
Spinal/epidural anaesthesia or puncture: There is a risk of epidural or spinal haematoma formation when neuraxial anaesthesia is performed in patients receiving antithrombotic agents. Edoxaban should be discontinued at least 24 hours before spinal or epidural procedures.
Premature discontinuation of any oral anticoagulant, including edoxaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. If edoxaban must be discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as directed by your physician.
Pregnancy and Breastfeeding
Pregnancy: There are limited data on the use of edoxaban in pregnant women. Animal studies have shown reproductive toxicity. Edoxaban is not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment. If pregnancy is suspected or confirmed, edoxaban should be discontinued and the patient counselled by a specialist regarding anticoagulation alternatives (typically low molecular weight heparin).
Breastfeeding: It is not known whether edoxaban is excreted in human breast milk. Animal data indicate that edoxaban is excreted in breast milk. A risk to the nursing infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from edoxaban therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Fertility: No human data on the effect of edoxaban on fertility are available. Animal studies did not show any adverse effects on fertility at clinically relevant doses.
How Does Edoxaban Sandoz Interact with Other Drugs?
Quick Answer: Edoxaban interacts with several important drug classes. P-glycoprotein (P-gp) inhibitors like ciclosporin and dronedarone require dose reduction. Antiplatelet agents, NSAIDs, and other anticoagulants increase bleeding risk. Strong P-gp inducers like rifampicin may reduce edoxaban's effectiveness.
Drug interactions with edoxaban primarily involve two pharmacological pathways: P-glycoprotein (P-gp) transport and pharmacodynamic interactions with other agents affecting haemostasis. Understanding these interactions is essential for safe prescribing and is a key reason why patients must always inform their healthcare provider of all medications they are taking, including over-the-counter products and herbal supplements.
Edoxaban is a substrate of the P-glycoprotein (P-gp) efflux transporter. Drugs that inhibit P-gp can increase edoxaban plasma concentrations, while P-gp inducers can decrease them. The clinical significance of these interactions has been evaluated in pharmacokinetic studies and clinical trials, informing the dose adjustment recommendations in the prescribing information.
Major Interactions
| Drug / Drug Class | Interaction Type | Clinical Significance | Management |
|---|---|---|---|
| Ciclosporin | P-gp inhibitor — increases edoxaban levels by ~73% | High — significantly increased bleeding risk | Reduce edoxaban dose to 30 mg once daily (or 15 mg if already on reduced dose) |
| Dronedarone | P-gp inhibitor — increases edoxaban levels by ~85% | High — significantly increased bleeding risk | Reduce edoxaban dose to 30 mg once daily (or 15 mg if already on reduced dose) |
| Ketoconazole | P-gp inhibitor — increases edoxaban levels by ~87% | High — significantly increased bleeding risk | Reduce edoxaban dose to 30 mg once daily (or 15 mg if already on reduced dose) |
| Warfarin / other anticoagulants | Pharmacodynamic — additive anticoagulant effect | Very high — major bleeding risk | Contraindicated (except during switching protocols) |
| Rifampicin | P-gp inducer — decreases edoxaban levels by ~34% | High — reduced anticoagulant efficacy | Avoid concurrent use; consider alternative anticoagulant |
| Phenytoin / Carbamazepine | P-gp inducer — may decrease edoxaban levels | Moderate — potential for reduced efficacy | Use with caution; monitor for signs of thromboembolism |
Minor Interactions
| Drug / Drug Class | Interaction Type | Clinical Significance | Management |
|---|---|---|---|
| Aspirin (low-dose) | Pharmacodynamic — increased bleeding risk | Moderate — dose-dependent bleeding increase | Use lowest effective aspirin dose; monitor for bleeding |
| Clopidogrel / Prasugrel | Pharmacodynamic — additive antiplatelet effect | Moderate to high — increased bleeding risk | Shortest duration possible; close monitoring |
| NSAIDs (ibuprofen, naproxen) | Pharmacodynamic — impaired platelet function + GI risk | Moderate — increased GI and overall bleeding | Avoid chronic NSAID use; use paracetamol when possible |
| SSRIs / SNRIs | Pharmacodynamic — serotonin-mediated platelet dysfunction | Low to moderate — marginally increased bleeding | Monitor for signs of bleeding; no dose adjustment |
| Verapamil | P-gp inhibitor — modest increase in edoxaban levels | Low — clinically non-significant increase | No dose adjustment required |
| Amiodarone | P-gp inhibitor — modest increase in edoxaban levels | Low — clinically non-significant increase | No dose adjustment required |
Edoxaban has minimal interaction with the CYP450 enzyme system, which is one of its advantages over older anticoagulants. It does not significantly inhibit or induce CYP enzymes, reducing the risk of metabolic drug interactions. However, patients should always report all medications, including herbal preparations such as St. John’s Wort (a P-gp inducer that may reduce edoxaban efficacy), to their healthcare provider.
What Is the Correct Dosage of Edoxaban Sandoz?
Quick Answer: The standard dose of edoxaban is 60 mg once daily. A reduced dose of 30 mg once daily is used for patients with renal impairment (CrCl 15–50 mL/min), low body weight (≤60 kg), or those on potent P-gp inhibitors. The 15 mg tablet is used in specific clinical scenarios. Always take edoxaban at the same time each day, with or without food.
Adults
| Indication | Standard Dose | Reduced Dose | Duration |
|---|---|---|---|
| Stroke prevention in NVAF | 60 mg once daily | 30 mg once daily | Long-term / indefinite |
| Treatment of DVT / PE | 60 mg once daily (after ≥5 days parenteral anticoagulation) | 30 mg once daily | Minimum 3 months; duration based on risk-benefit |
| Prevention of recurrent VTE | 60 mg once daily | 30 mg once daily | Based on individual risk assessment |
Dose reduction criteria: The dose should be reduced from 60 mg to 30 mg once daily in patients with any one of the following:
- Moderate or severe renal impairment (creatinine clearance 15–50 mL/min)
- Low body weight ≤60 kg
- Concomitant use of potent P-glycoprotein inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole
The 15 mg tablet may be prescribed in specific clinical situations where further dose adjustment is appropriate, such as when multiple dose-reduction factors coexist or during anticoagulant switching protocols. Your doctor will make this determination based on your individual circumstances.
Children
Edoxaban Sandoz is not approved for use in children and adolescents under 18 years of age. There is currently insufficient evidence regarding the safety and efficacy of edoxaban in the paediatric population. Clinical trials in paediatric patients are ongoing under regulatory requirements. For children requiring anticoagulation, alternative agents such as low molecular weight heparin or warfarin (with appropriate INR monitoring) are typically used under specialist supervision.
Elderly
No dose adjustment is required based on age alone. However, elderly patients (≥75 years) frequently have age-related decline in renal function, lower body weight, and increased baseline bleeding risk. These factors may independently necessitate dose reduction to 30 mg once daily. Close monitoring for signs of bleeding is recommended in elderly patients. The ENGAGE AF-TIMI 48 trial included a substantial proportion of patients aged ≥75, confirming the benefit-risk profile in this age group, with notably lower rates of intracranial haemorrhage compared to warfarin.
Missed Dose
If you forget to take a dose, take it as soon as you remember on the same day. Do not take a double dose to compensate for the missed one. Resume your normal dosing schedule the following day. If you are unsure what to do, contact your pharmacist or doctor for advice. Setting a daily alarm or using a pill organiser may help ensure consistent adherence to your medication schedule.
Overdose
Overdose of edoxaban may lead to excessive anticoagulation and an increased risk of bleeding. There is no specific antidote for general overdose situations, although andexanet alfa has been approved for reversal of life-threatening or uncontrolled bleeding associated with Factor Xa inhibitors. Management of overdose is primarily supportive and may include:
- Activated charcoal within 2 hours of ingestion to reduce absorption
- Symptomatic treatment and monitoring of vital signs
- Use of prothrombin complex concentrates (PCC) if clinically significant bleeding occurs
- Fresh frozen plasma or platelet transfusions as clinically indicated
- Haemodialysis does not significantly remove edoxaban from the bloodstream (approximately 9% removed in 4 hours) due to high protein binding
If you suspect an overdose of edoxaban, seek emergency medical attention immediately. Contact your local poison control centre or emergency services. Bring the medication packaging with you to assist healthcare providers in managing your care.
What Are the Side Effects of Edoxaban Sandoz?
Quick Answer: The most common side effects of edoxaban are bleeding-related events, including skin and soft-tissue bleeding, nosebleeds, and gastrointestinal bleeding. Anaemia and abnormal liver function tests may also occur. Most side effects are dose-related, and the 15 mg dose carries a lower bleeding risk than the standard 60 mg dose.
Like all medicines, edoxaban can cause side effects, although not everybody gets them. The primary safety concern with any anticoagulant is bleeding. The type, severity, and frequency of bleeding events have been extensively characterised in clinical trials, most notably the ENGAGE AF-TIMI 48 trial (atrial fibrillation) and the Hokusai-VTE trial (venous thromboembolism). Below is a comprehensive breakdown of side effects by frequency category, as defined by the Council for International Organizations of Medical Sciences (CIOMS) and the EMA:
Very Common (>1 in 10 patients)
- Cutaneous soft tissue bleeding (bruising, skin haemorrhage, petechiae, ecchymosis)
Common (1 in 10 to 1 in 100 patients)
- Epistaxis (nosebleeds)
- Lower gastrointestinal bleeding (rectal, haemorrhoidal)
- Upper gastrointestinal bleeding (gastric, oesophageal)
- Oral/pharyngeal bleeding (gum bleeding)
- Anaemia
- Elevated liver transaminases (ALT, AST)
- Elevated bilirubin
- Elevated gamma-glutamyltransferase (GGT)
- Microscopic haematuria (blood in urine)
- Vaginal bleeding (in women)
- Rash
- Pruritus (itching)
Uncommon (1 in 100 to 1 in 1,000 patients)
- Intracranial haemorrhage (bleeding in the brain)
- Surgical site haemorrhage
- Haemoptysis (coughing up blood)
- Allergic oedema (localised swelling)
- Urticaria (hives)
- Thrombocytopenia (low platelet count)
- Dizziness
- Headache
- Nausea
- Abdominal pain
Rare (<1 in 1,000 patients)
- Anaphylactic reaction / anaphylactic shock
- Intraocular bleeding (bleeding in the eye)
- Pericardial haemorrhage (bleeding around the heart)
- Retroperitoneal bleeding
- Intra-articular bleeding (joint bleeding)
- Subdural haematoma
- Procedural haematoma (spinal/epidural)
When to Seek Immediate Medical Attention
Contact your doctor or seek emergency medical care immediately if you experience any of the following while taking edoxaban:
- Unusual, prolonged, or excessive bleeding from cuts or wounds
- Blood in your urine (pink, red, or dark brown), stools (red or black/tarry), or vomit (red or coffee-ground appearance)
- Unexplained bruising or bruises that increase in size
- Sudden severe headache, confusion, vision changes, weakness, numbness, or difficulty speaking (signs of intracranial bleeding/stroke)
- Coughing up blood or blood-streaked sputum
- Prolonged or heavy menstrual bleeding
- Signs of severe allergic reaction: swelling of the face, lips, tongue, or throat; difficulty breathing; widespread rash or hives
- Unexplained drop in blood pressure, dizziness, or fainting
The rate of clinically significant bleeding with edoxaban has been shown to be lower than with dose-adjusted warfarin in large clinical trials. In the ENGAGE AF-TIMI 48 trial, major bleeding occurred in 2.75% per year with the higher-dose edoxaban regimen compared to 3.43% per year with warfarin — representing a 20% relative risk reduction. The lower-dose regimen showed an even greater reduction in bleeding events.
How Should You Store Edoxaban Sandoz?
Quick Answer: Store Edoxaban Sandoz at room temperature (below 30°C / 86°F) in the original packaging, protected from moisture. Keep out of reach and sight of children. Do not use after the expiry date printed on the packaging.
Proper storage of medications is essential to maintain their efficacy and safety throughout the shelf life. Edoxaban Sandoz film-coated tablets should be stored according to the following guidelines:
- Temperature: Store below 30°C (86°F). Do not freeze. Avoid exposure to extreme heat or direct sunlight.
- Moisture protection: Keep the tablets in the original blister packaging until the time of use. The blister packaging provides protection against moisture, which can degrade the active ingredient.
- Child safety: Store in a secure location out of the reach and sight of children. Accidental ingestion of anticoagulants by children can be life-threatening.
- Expiry date: Do not use Edoxaban Sandoz after the expiry date which is stated on the carton and blister after “EXP”. The expiry date refers to the last day of that month.
- Disposal: Do not throw away any medicines via wastewater or household waste. Return unused or expired medications to your local pharmacy for safe disposal. This helps protect the environment from pharmaceutical contamination.
If you notice any change in the appearance of the tablets (discolouration, crumbling, unusual odour), do not take them and consult your pharmacist. Tablets that have been removed from their blister packaging and not taken should be discarded and not returned to the blister.
What Does Edoxaban Sandoz Contain?
Quick Answer: Each Edoxaban Sandoz 15 mg film-coated tablet contains edoxaban tosilate monohydrate as the active ingredient, equivalent to 15 mg of edoxaban. The tablets also contain inactive ingredients (excipients) that help form the tablet and its film coating.
Active Ingredient
The active substance is edoxaban (as edoxaban tosilate monohydrate). Each film-coated tablet contains edoxaban tosilate monohydrate equivalent to 15 mg of edoxaban. Edoxaban tosilate monohydrate is a white to off-white crystalline powder with the molecular formula C24H30ClN7O4S · C7H8O3S · H2O and a molecular weight of approximately 738.27 g/mol (tosilate monohydrate form).
Inactive Ingredients (Excipients)
The inactive ingredients serve various pharmaceutical functions including tablet binding, disintegration, lubrication, and film coating. Typical excipients found in edoxaban film-coated tablets include:
- Tablet core: Mannitol, pregelatinised starch, crospovidone, hydroxypropylcellulose, magnesium stearate
- Film coating: Hypromellose, macrogol, titanium dioxide (E171), talc, iron oxide (colourant)
Patients with known hypersensitivity to any of the excipients listed should inform their prescriber before starting treatment. The 15 mg tablet is typically a small, round, film-coated tablet with a distinctive appearance for identification purposes. The exact appearance (colour, markings, shape) may vary depending on the specific manufacturer and market. Refer to the patient information leaflet supplied with your specific product for detailed tablet description.
Edoxaban Sandoz is a generic medicine, meaning it contains the same active substance and has been demonstrated to be bioequivalent to the reference product through rigorous pharmacokinetic studies reviewed by regulatory authorities. The EMA requires that generic medicines demonstrate the same bioavailability as the originator product, ensuring comparable clinical efficacy and safety. Minor differences in excipients are allowed but must not affect the therapeutic performance of the medicine.
Frequently Asked Questions About Edoxaban Sandoz
Edoxaban Sandoz is a direct oral anticoagulant (DOAC) prescribed for two main indications: (1) prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation who have risk factors for stroke, and (2) treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults. The 15 mg tablet is the reduced-dose formulation, used in patients with specific clinical considerations such as low body weight, renal impairment, or concurrent use of certain P-glycoprotein inhibitors.
Edoxaban and warfarin are both anticoagulants but work through different mechanisms. Edoxaban directly inhibits Factor Xa, while warfarin blocks vitamin K-dependent clotting factor synthesis. Key practical differences include: edoxaban requires no routine INR blood monitoring, has fewer dietary and drug interactions, has a rapid onset (1–2 hours vs. days for warfarin), uses fixed dosing, and has a more predictable anticoagulant effect. However, warfarin has a longer track record, an established reversal agent (vitamin K), and remains preferred for patients with mechanical heart valves.
Combining edoxaban with aspirin, clopidogrel, or other anticoagulants significantly increases your risk of bleeding. Concurrent use with other anticoagulants (warfarin, heparin, other DOACs) is generally contraindicated. If dual therapy with an antiplatelet agent is medically necessary (for example, after coronary stenting), your doctor will use the lowest effective doses for the shortest time possible while closely monitoring you for bleeding complications. Always tell your doctor about all medicines you take, including over-the-counter pain relievers and NSAIDs.
If you miss a dose, take it as soon as you remember on the same day. Do not take a double dose the next day to make up for the missed one. Simply resume your regular dosing schedule the following day. If you have any concerns, contact your pharmacist or prescribing doctor. Maintaining consistent daily dosing is important for effective anticoagulation.
Yes. Andexanet alfa (marketed as Ondexxya in Europe and Andexxa in the US) is a specific reversal agent approved for Factor Xa inhibitors including edoxaban. It works by binding to edoxaban and neutralising its anticoagulant effect. In hospital emergency settings, prothrombin complex concentrates (PCC) may also be administered. Additionally, due to edoxaban's relatively short half-life (10–14 hours), simply stopping the medication will allow the anticoagulant effect to diminish significantly within 24 hours in most patients.
Yes. Unlike warfarin, which requires careful monitoring of vitamin K intake from green leafy vegetables, edoxaban has no significant dietary interactions. You can take edoxaban with or without food. The absorption of edoxaban is not meaningfully affected by food intake. However, you should maintain a healthy, balanced diet and inform your doctor if you make significant changes to your diet or begin taking any nutritional supplements.
References
This article is based on the following peer-reviewed sources and international guidelines:
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907 (ENGAGE AF-TIMI 48 trial)
- Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415. doi:10.1056/NEJMoa1306638
- European Medicines Agency (EMA). Edoxaban — Summary of Product Characteristics (SmPC). EMA/CHMP. Available at: ema.europa.eu
- European Society of Cardiology (ESC). 2024 Guidelines for the Management of Atrial Fibrillation. Eur Heart J. 2024. doi:10.1093/eurheartj/ehae176
- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. doi:10.1093/europace/euab065
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051
- World Health Organization (WHO). Model List of Essential Medicines — 23rd List (2023). Geneva: WHO.
- British National Formulary (BNF). Edoxaban tosilate monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. doi:10.1016/S0140-6736(13)62343-0
- International Society on Thrombosis and Haemostasis (ISTH). Guidance on anticoagulant reversal strategies. J Thromb Haemost. 2022.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians specialising in clinical pharmacology, cardiology, and haematology.
Medical Writing
iMedic Medical Editorial Team — Specialists in clinical pharmacology and evidence-based medicine. All content follows the GRADE evidence framework and is based on systematic reviews of randomised controlled trials.
Medical Review
iMedic Medical Review Board — Independent panel of medical experts who review all content according to international guidelines from the EMA, WHO, ESC, AHA/ACC, and ISTH.
All medical content on iMedic is independently written and reviewed by licensed physicians. We have no commercial funding, no pharmaceutical company sponsorship, and no advertising. Our content follows the GRADE evidence framework and is based on the highest quality available evidence. Read more about our editorial standards.